| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Quince Therapeutics, Inc. (QNCX) has 7 insiders with recent SEC Form 4 filings, including 4 buys and 0 sells. QNCX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 739.9K | $699.2K | - | |
| COO | 45.2K | $42.7K | - | |
| ? | 39.2K | $37.0K | - | |
| ? | 29.4K | $27.8K | - | |
| ? | 21.8K | $20.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 13, 2019 | McLoughlin Margaret58 | Director | Buy | 550 | $17.00 | $9,350.00 | New | |
| May 10, 2019 | Epiq Capital Group, LLC | Ia/ Managing Member 10% Owner | Buy | 8,600 | $26.98 | $232,056.10 | +0.1% |